We are live on ! Find out more
LAB icon

Standard BioTools

99 hedge funds and large institutions have $702M invested in Standard BioTools in 2014 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 43 increasing their positions, 34 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

26% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 34

16% more call options, than puts

Call options by funds: $2.86M | Put options by funds: $2.47M

5% less funds holding

Funds holding: 10499 (-5)

11% less capital invested

Capital invested by funds: $788M → $702M (-$85.9M)

28% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 18

Holders
99
Holders Change
-5
Holders Change %
-4.81%
% of All Funds
2.87%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
13
Increased
43
Reduced
34
Closed
18
Calls
$2.86M
Puts
$2.47M
Net Calls
+$395K
Net Calls Change
-$12.9M
Name Holding Trade Value Shares
Change
Change in
Stake
Primecap Management
1
Primecap Management
California
$90.4M +$1.08M +38,300 +1%
Jennison Associates
2
Jennison Associates
New York
$77.7M +$2.44M +86,738 +3%
JP Morgan Chase
3
JP Morgan Chase
New York
$61.7M +$370K +13,175 +0.5%
O
4
OrbiMed
New York
$51.5M +$6.69M +238,000 +13%
Franklin Resources
5
Franklin Resources
California
$46.4M +$15.3M +544,577 +40%
WA
6
Wasatch Advisors
Utah
$43.4M +$860K +30,588 +2%
NCGI
7
Next Century Growth Investors
Minnesota
$36.6M +$6.79M +241,495 +19%
Fidelity Investments
8
Fidelity Investments
Massachusetts
$25.2M -$2.79M -99,302 -9%
Vanguard Group
9
Vanguard Group
Pennsylvania
$20.9M +$186K +6,612 +0.8%
Invesco
10
Invesco
Georgia
$20.5M +$14.7M +521,223 +165%
BFA
11
BlackRock Fund Advisors
California
$18.6M -$788K -28,018 -4%
Lord, Abbett & Co
12
Lord, Abbett & Co
New Jersey
$18.4M +$2.55M +90,692 +14%
Schroder Investment Management Group
13
Schroder Investment Management Group
United Kingdom
$14.3M +$8.26M +293,800 +101%
RG
14
Redmile Group
California
$13.7M +$4.7M +167,082 +43%
Luther King Capital Management (LKCM)
15
Luther King Capital Management (LKCM)
Texas
$13.7M +$15.7M +559,231 New
RIM
16
RS Investment Management
California
$13.2M +$340K +12,100 +2%
ZCI
17
Zevenbergen Capital Investments
Washington
$11.2M -$3.29M -116,850 -20%
State Street
18
State Street
Massachusetts
$10.2M +$27.3K +972 +0.2%
Northern Trust
19
Northern Trust
Illinois
$8.87M +$1.17M +41,751 +13%
BIT
20
BlackRock Institutional Trust
California
$7.97M -$547K -19,454 -6%
CGI
21
CI Global Investments
California
$7.52M +$197K +7,000 +2%
SIMG
22
Stephens Investment Management Group
Texas
$6.69M +$1.23M +43,715 +19%
Millennium Management
23
Millennium Management
New York
$5.82M -$781K -27,784 -10%
RFC
24
Russell Frank Company
Washington
$5.74M +$929K +33,052 +16%
FC
25
FIC Capital
New York
$4.62M +$5.31M +188,700 New

LAB Hedge Fund Activity: Q3 2014 in Review

99 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q3 2014, worth a combined $702M — down 11% from $788M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of LAB and 13 opened new positions — a net loss of 5 holders — while 34 trimmed existing stakes and 43 added.

The largest buyer was Luther King Capital Management (LKCM), opening a new position worth an estimated $15.7M. The largest seller was Pier Capital, exiting entirely with an estimated $7.47M sold.

  • 99 institutional investors held Standard BioTools (LAB) as of Q3 2014, down from 104 in Q2 2014.
  • Funds reported $702M of Standard BioTools stock for Q3 2014, down 11% quarter-over-quarter.
  • 13 funds opened new Standard BioTools positions in Q3 2014 and 18 closed out, a net change of -5 holders.
  • The largest Standard BioTools buyer in Q3 2014 was Luther King Capital Management (LKCM), an estimated $15.7M added.
  • The largest Standard BioTools seller in Q3 2014 was Pier Capital, an estimated $7.47M sold.

Based on aggregated 13F filings for Q3 2014.